ArticleHepatology (Baltimore, Md.)2019
Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection.
Open access · bronzeAbstract readMulticenter Study
In one paragraph
Article in Hepatology (Baltimore, Md.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 48 citations in OpenAlex.
- Viral persistence and immune dysfunction in chronic hepatitis B: Mechanisms of post-treatment antigen asynchrony.iScience · 2026Review
- Pegylated Interferon-based Treatment Improves Response Rates in Immune-tolerant Patients with Chronic Hepatitis B: A Prospective Trial.Journal of clinical and translational hepatology · 2026Article
- Review
- Scientific and medical evidence informing expansion of hepatitis B treatment guidelines.The lancet. Gastroenterology & hepatology · 2025Review
- Article
- Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.Hepatology (Baltimore, Md.) · 2023Article
- Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference.Journal of hepatology · 2023Review
- Functional Cure of Chronic Hepatitis B with Antiviral Treatment in Children having High-level Viremia and Normal or Mildly Elevated Serum Aminotransferase.Journal of clinical and translational hepatology · 2023Article
- Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections.Gut · 2023Article
- Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023Article
- Immunostaining for hepatitis B viral antigens in liver: Association with clinical, biochemical, and virologic features of disease.Journal of gastroenterology and hepatology · 2023Article
- Review
- Racial Disparities in Treatment Initiation and Outcomes of Chronic Hepatitis B Virus Infection in North America.JAMA network open · 2023Observational
- The scientific basis of combination therapy for chronic hepatitis B functional cure.Nature reviews. Gastroenterology & hepatology · 2023Review
- [Clinical trials considerations for patients with immune-tolerant phase chronic hepatitis B].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Review
- Aiming for Functional Cure With Established and Novel Therapies for Chronic Hepatitis B.Hepatology communications · 2022Review
- Article
- Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy.Hepatology (Baltimore, Md.) · 2021Article
- Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections.The Journal of infectious diseases · 2021Article
- CON: All Patients With Immune-Tolerated Hepatitis B Virus Do Not Need to Be Treated.Clinical liver disease · 2020Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 9 institutions in 2 countries.
Jordan J FeldToronto Centre for Liver Disease, University of Toronto, Toronto, Canada.
Norah A TerraultUniversity of California San Francisco, San Francisco, CA.
Hsing-Hua S LinGraduate School of Public Health, University of Pittsburgh, Pittsburgh, PA.
Steven H BelleGraduate School of Public Health, University of Pittsburgh, Pittsburgh, PA.
Raymond T ChungMassachusetts General Hospital, Harvard University, Boston, MA.
Naoky TsaiUniversity of Hawaii, Honolulu, HI.
Mandana KhaliliUniversity of California San Francisco, San Francisco, CA.
Robert PerrilloBaylor University Medical Center, Baylor University, Dallas, TX.
Stewart L CooperSan Francisco Center for Liver Disease, California Pacific Medical Center, San Francisco, CA.
Marc G GhanyLiver Diseases Branch, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.ORCID 0000-0003-2837-0188
Harry L A JanssenToronto Centre for Liver Disease, University of Toronto, Toronto, Canada.
Anna S LokUniversity of Michigan, Ann Arbor, MI.
Hepatitis B Research NetworkThe Hepatitis B Research Network.
University of California, San Francisco · USUniversity of Pittsburgh · USUniversity of Toronto · CABaylor University Medical Center · USCalifornia Pacific Medical Center · USHarvard University · USNational Institutes of Health · USUniversity of Hawaiʻi at Mānoa · USUniversity of Michigan · US
Funding
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0MMichigan Institute for Clinical and Health Research (MICHR)UL1TR002240 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUMENG, JULIE C, MASHOUR, GEORGE ALEXANDER · 2017 to 2022
$54.9MMICHIGAN INSTITUTE FOR CLINICAL AND HEALTH RESEARCH (MICHR) (UL1): (BPCA)UL1RR024986 · NCRR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHANLEY, THOMAS P. · 2007 to 2011
$51.2MNorth Carolina Translational & Clinical Sciences Institute (NC TraCS)UL1TR001111 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, CAREY, TIMOTHY S · 2013 to 2017
$43.9MTRANSGENIC AND CHIMERIC MOUSE COREP30DK050306 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Ken Hashigiwa Cadwell · 1997 to 2026
$32.5MHepatitis B Research Network - Data Coordination CenterU01DK082864 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BELLE, STEVEN H. · 2008 to 2019
$25.3MZDV VS ZDV + DDL VS ZDV + DDL + NVP IN ASYMPTOMATIC HIV PATIENTSM01RR000040 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 1985 to 2006
$21.1MCenter for Clinical and Translational ResearchUL1TR000058 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2012 to 2015
$12.5MHepatitis B Research Network (HBRN): Natural History and Treatment StudiesU01DK082944 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COOPER, STEWART, KHALILI, MANDANA · 2008 to 2019
$10.0MNatural History, Therapy and Pathogenesis of Chronic Viral Hepatitis BZIADK054517 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI GHANY, MARC · 2009 to 2025
$9.6MObservation Study of Persons with Chronic Hepatitis B Virus infection in North AmericaU01DK082874 · NIDDK · UNIVERSITY HEALTH NETWORK · PI JANSSEN, HARRY · 2008 to 2019
$6.9MHarvard Hepatitis B ConsortiumU01DK082919 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CHUNG, RAYMOND T, LAU, DARYL T · 2008 to 2019
$4.7MClinical and Translational Science Awards [CTSA] U54 TR001959Clinical and Translational Science Awards [CTSA] UL1T R001111NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR000058NCATS NIH HHS UL1 TR002240NCRR NIH HHS M01 RR000040NCRR NIH HHS UL1 RR024986NIDDK NIH HHS A-DK-3002-001NIDDK NIH HHS P30 DK050306NIDDK NIH HHS U01 DK082843NIDDK NIH HHS U01 DK082863NIDDK NIH HHS U01 DK082864NIDDK NIH HHS U01 DK082866NIDDK NIH HHS U01 DK082867NIDDK NIH HHS U01 DK082871NIDDK NIH HHS U01 DK082872NIDDK NIH HHS U01 DK082874NIDDK NIH HHS U01 DK082919NIDDK NIH HHS U01 DK082923NIDDK NIH HHS U01 DK082927NIDDK NIH HHS U01 DK082943NIDDK NIH HHS U01 DK082944
Abstract
Monotherapy with interferon or nucleoside analog is generally not recommended during the immune-tolerant (IT) phase of chronic hepatitis B virus (HBV) infection. Recognition that high HBV DNA levels are associated with hepatocellular carcinoma has increased interest in treating HBV in the IT phase. Small pediatric studies reported efficacy with combination nucleoside analog and interferon therapy. The aim of this study was to evaluate the safety and efficacy of the combination of entecavir and peginterferon in adults in the IT phase of chronic HBV infection. Hepatitis B e antigen (HBeAg)-positive adults with HBV DNA > 10
Indexed as
AdultCanadaCohort StudiesDNA, ViralDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFemaleFollow-Up StudiesGuanineHepatitis B, ChronicHepatitis B e AntigensHumansInterferon-alphaInternationalityMaleDNA, ViralentecavirGuanineHepatitis B e AntigensInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsRecombinant Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.